Analysts Offer Predictions for Sanofi SA’s Q1 2020 Earnings (NYSE:SNY)

Sanofi SA (NYSE:SNY) – Stock analysts at Svb Leerink issued their Q1 2020 EPS estimates for Sanofi in a report released on Tuesday, February 11th. Svb Leerink analyst G. Porges forecasts that the company will post earnings per share of $0.81 for the quarter. Svb Leerink has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for Sanofi’s Q2 2020 earnings at $0.78 EPS, Q3 2020 earnings at $1.03 EPS, Q4 2020 earnings at $0.82 EPS, FY2023 earnings at $4.31 EPS and FY2024 earnings at $4.61 EPS.

Several other analysts have also recently commented on the company. Leerink Swann started coverage on Sanofi in a report on Tuesday. They issued a “market perform” rating and a $58.00 price target for the company. DZ Bank restated a “neutral” rating on shares of Sanofi in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Sunday, January 5th. They noted that the move was a valuation call. Barclays cut Sanofi from an “equal weight” rating to an “underweight” rating in a report on Friday, December 6th. Finally, Liberum Capital cut Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $52.25.

Sanofi stock opened at $50.62 on Thursday. The stock has a market cap of $127.91 billion, a PE ratio of 16.17, a P/E/G ratio of 2.41 and a beta of 0.67. The stock has a 50-day moving average price of $50.26 and a 200 day moving average price of $46.43. Sanofi has a 52 week low of $40.00 and a 52 week high of $51.84. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Atria Investments LLC bought a new stake in shares of Sanofi in the 2nd quarter worth about $225,000. Reilly Financial Advisors LLC lifted its holdings in shares of Sanofi by 8,332.8% in the 3rd quarter. Reilly Financial Advisors LLC now owns 26,985 shares of the company’s stock worth $1,250,000 after acquiring an additional 26,665 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Sanofi by 21.8% in the 3rd quarter. Signaturefd LLC now owns 14,001 shares of the company’s stock worth $649,000 after acquiring an additional 2,507 shares during the last quarter. Advisor Partners LLC lifted its holdings in shares of Sanofi by 17.5% in the 3rd quarter. Advisor Partners LLC now owns 9,332 shares of the company’s stock worth $432,000 after acquiring an additional 1,392 shares during the last quarter. Finally, Vista Private Wealth Partners. LLC bought a new stake in shares of Sanofi in the 3rd quarter worth about $96,000. Institutional investors own 7.04% of the company’s stock.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: Hedge Funds Explained

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.